Erik A C Wiemer
Affiliation: Erasmus MC
Country: The Netherlands
- The role of microRNAs in cancer: no small matterErik A C Wiemer
Department of Medical Oncology, Josephine Nefkens Institute, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
Eur J Cancer 43:1529-44. 2007....
- RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic responseHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam Daniel den Hoed Kliniek Josephine Nefkens Institute, 3000 DR Rotterdam, The Netherlands
Clin Cancer Res 9:827-36. 2003..The aim of this study was to investigate whether expression of particular drug resistance genes in primary operable breast cancer correlates with response to first-line chemotherapy in advanced disease...
- Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumpsHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam-Josephine Nefkens Institute, Rotterdam, The Netherlands
Cancer Biol Ther 4:747-52. 2005....
- Drug transporters of platinum-based anticancer agents and their clinical significanceHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Drug Resist Updat 14:22-34. 2011..In addition, transporter-mediated tumour resistance, the impact of potential platinum transporter-mediated drug-drug interactions, and the role of drug transporters in the renal elimination of platinum compounds are discussed...
- Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometryWalter J Loos
Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
J Pharm Biomed Anal 54:387-94. 2011..7 to 110.6%. The applicability of the bioanalytical method was demonstrated and is currently implemented in a clinical trial to study DM as probe-drug for individualized tamoxifen treatment in breast cancer patients...
- Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulationMaja J A de Jonge
Erasmus University Medical Center Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
Eur J Cancer 46:3016-21. 2010..v.) LiPlaCis. and to assess plasma and urine pharmacokinetics and plasma biomarkers...
- Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis studyInge R H M Konings
Department of Medical Oncology, Erasmus University Medical Center, Room HE 118, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
Cancer Chemother Pharmacol 67:1055-62. 2011..Sampling for measurement of 5-fluorouracil in tumor tissue was performed using microdialysis...
- Application of prolonged microdialysis sampling in carboplatin-treated cancer patientsInge R H M Konings
Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
Cancer Chemother Pharmacol 64:509-16. 2009..We explored the feasibility of microdialysis in tumor tissue for multiple days in a clinical setting, using carboplatin as model drug...
- ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patientsBronno van der Holt
Department of Trials and Statistics HOVON Dutch Belgian Hemato Oncology Cooperative Group Data Center, Erasmus MC Daniel den Hoed Cancer Center and Sophia Children s Hospital, Rotterdam, The Netherlands
Clin Pharmacol Ther 80:427-39. 2006....
- Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genesHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands
Cancer Biol Ther 4:1270-4. 2005..The latter may imply that these wild-type c-KIT and PDGFR tumor types will probably not benefit from imatinib treatment...
- Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam, Daniel den Hoed Kliniek Josephine Nefkens Institute, Rotterdam, The Netherlands
Blood 104:2940-2. 2004..Since BCRP is highly expressed in the gastrointestinal tract, BCRP might not only play a role in cellular resistance of tumor cells but also influence the gastrointestinal absorption of imatinib...
- Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancerJohn A Foekens
Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute, 3000 CA Rotterdam, The Netherlands
Proc Natl Acad Sci U S A 105:13021-6. 2008..In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein...
- Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostaticsMarieke H Mossink
Department of Hematology, Erasmus University Rotterdam, 3015 GE Rotterdam, The Netherlands
Cancer Res 62:7298-304. 2002..Both groups of mice responded similarly to the doxorubicin treatment. Our results suggest that MVP/vaults are not directly involved in the resistance to cytostatic agents...
- MicroRNAs in ovarian cancer biology and therapy resistanceMarijn T M van Jaarsveld
Dept of Medical Oncology, Josephine Nefkens Institute, Erasmus MC, 3015 GE Rotterdam, The Netherlands
Int J Biochem Cell Biol 42:1282-90. 2010..In the final section, we speculate on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools...
- The relevance of microdialysis for clinical on:cologyJos J E M Kitzen
Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Curr Clin Pharmacol 1:255-63. 2006..Although faced with some methodological challenges, the technique offers many advantages over others, and enables direct tumor assessment for pharmacokinetics and even pharmacodynamics...
- Vaults: a ribonucleoprotein particle involved in drug resistance?Marieke H Mossink
Department of Hematology, Erasmus Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
Oncogene 22:7458-67. 2003..Here, we review the current knowledge on the vault complex and critically discuss the evidence that links vaults to drug resistance...
- Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expressionArend van Zon
Department of Hematology, Erasmus Medical Center, 3000 DR Rotterdam, The Netherlands
Cancer Res 64:4887-92. 2004..Our results indicate that vaults are not directly involved in the sequestration of anthracyclines in vesicles nor in their efflux from the nucleus...
- The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signalingSivanagarani Kolli
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520 8066, USA
J Biol Chem 279:29374-85. 2004..We propose that MVP functions as a novel scaffold protein for both SHP-2 and Erk. The regulation of MVP tyrosyl phosphorylation by SHP-2 may play an important role in cell survival signaling...
- Major vault protein, in concert with constitutively photomorphogenic 1, negatively regulates c-Jun-mediated activator protein 1 transcription in mammalian cellsChunling Yi
Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520 8104, USA
Cancer Res 65:5835-40. 2005..Taken together, we propose that MVP, most likely through its interaction with COP1, suppresses c-Jun-mediated AP-1 transcription under unstressed conditions, thereby preventing cells from undergoing stress response...
- Up-regulation of drug resistance-related vaults during dendritic cell developmentAnouk B Schroeijers
Departments of. Pathology and Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
J Immunol 168:1572-8. 2002..These data point to a role for vaults in both DC survival and functioning as APC...